Drag a card by its title · ⚙ to size, swap or remove

The company

Stereotaxis, Inc.

STXS · NYSE American

Health CareMedical DevicesNot moving yetRobotics

STXS stood above a rising 150-day average in 5 of the last 52 weekly readings, and has been out of that trend for the last 39 weeks. It is 38.0% below that average now. Medical Devices: 29% of its 181 stocks in an uptrend (−4 points in four weeks); Health Care: 28% (−6 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 39
Industry in uptrend: 29% -4 in 4 wk
Insider buys, 12 months: $67K
Insider sales, 12 months: $0
Officials’ trades on record: 0
Institutions holding: 107 (-4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 5 of 52 weeks.

22 Apr – 21 Oct

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2

Sale orders, 12 months0

Buyers · sellers1 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders107-4 on the quarter

New · exited16 · 20

Reported value$69.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
DAFNA Capital Management LLCunchanged · filed 14 Aug 2026	13,680,554$23.5M	00.0%
BlackRock, Inc.added · filed 7 Aug 2026	4,396,835$7.6M	+440,592+11.1%
Lagoda Investment Management, L.P.reduced · filed 14 Aug 2026	4,122,600$7.1M	-227,800−5.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	3,044,820$5.2M	+46,776+1.6%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	1,895,243$3.3M	+219,835+13.1%
ESSEX INVESTMENT MANAGEMENT CO LLCreduced · filed 6 Aug 2026	1,521,966$2.6M	-68,135−4.3%
Archon Capital Management LLCunchanged · filed 14 Aug 2026	1,226,044$2.1M	00.0%
Warberg Asset Management LLCadded · filed 11 Aug 2026	1,108,889$1.9M	+14,766+1.3%
STATE STREET CORPreduced · filed 7 Aug 2026	916,780$1.6M	-40,988−4.3%
AlphaCentric Advisors LLCunchanged · filed 24 Jul 2026	600,000$1.0M	00.0%

31 Mar 2023 – 30 Jun 2026

News

No headline names it lately.

Everyone who traded it

Arun Swarup Menawat Director · last 1 Jul 20260 · 0

David Benfer Director · last 1 Jul 20268 · 2

Myriam Curet Director · last 1 Jul 20260 · 0

Nachum Shamir Director · last 1 Jul 20260 · 0

Nathan Fischel Director, 10% owner · last 1 Jul 20260 · 0

Ross B. Levin Director · last 1 Jul 20260 · 0

Kimberly R. Peery Chief Financial Officer · last 11 Apr 20260 · 0

Paul J. Isaac Director, Other · last 17 Nov 202547 · 25

Robert J. Messey Director · last 2 Jan 20242 · 1

David Leo Fischel Chief Executive Officer · last 20 May 20210 · 0

Joe E. Kiani Director, 10% owner · last 4 Jan 20210 · 0

Kevin M. Barry Chief Legal Officer&Secretary · last 3 Mar 20190 · 0

Same industry

RCEL Avita MedicalLeading+127%

HTFL HeartflowLeading+59%

PLSE Pulse BiosciencesLeading+51%

ATRC AtriCureLeading+51%

HAE HaemoneticsLeading+44%

INFU InfuSystems HoldingsLeading+32%

OBIO Orchestra BioMed HoldingsLeading+27%

BVS BioventusLeading+24%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202552.7%

Operating profit marginFY 2025 · to 31 Dec 2025-68.3%

Free cash flow marginFY 2025 · to 31 Dec 2025-42.6%

Return on capital employedFY 2025 · to 31 Dec 2025-74.0%

Interest coverFY 2025 · to 31 Dec 2025-47.35×

Research spendFY 2025 · to 31 Dec 202529.0%

Share count trendFY 2025 · to 28 Feb 20266.9%

Cash and equivalentsFY 2025 · to 31 Dec 2025$13.4M

Free cash flowFY 2025 · to 31 Dec 2025−$13.8M

Analyst forecasts

No analyst forecasts yet.